Early Gut-Bacteria pill tested for bowel disease control
NCT ID NCT05852574
Summary
This early-stage study is testing a new oral treatment called CP101, which contains specific gut bacteria, in people with mild-to-moderate ulcerative colitis. The main goals are to see if the treatment safely establishes itself in the gut and if it helps control the disease. About 30 participants will take different dosing schedules and be followed for 24 weeks to monitor their response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.